AU2014361822A1 - Treating brain disorders and biomarkers related thereto - Google Patents

Treating brain disorders and biomarkers related thereto Download PDF

Info

Publication number
AU2014361822A1
AU2014361822A1 AU2014361822A AU2014361822A AU2014361822A1 AU 2014361822 A1 AU2014361822 A1 AU 2014361822A1 AU 2014361822 A AU2014361822 A AU 2014361822A AU 2014361822 A AU2014361822 A AU 2014361822A AU 2014361822 A1 AU2014361822 A1 AU 2014361822A1
Authority
AU
Australia
Prior art keywords
disorder
patient
brain
glyx
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014361822A
Other languages
English (en)
Inventor
Joseph Moskal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of AU2014361822A1 publication Critical patent/AU2014361822A1/en
Priority to AU2019264583A priority Critical patent/AU2019264583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
AU2014361822A 2013-12-13 2014-12-15 Treating brain disorders and biomarkers related thereto Abandoned AU2014361822A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019264583A AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915835P 2013-12-13 2013-12-13
US61/915,835 2013-12-13
PCT/US2014/070340 WO2015089503A2 (en) 2013-12-13 2014-12-15 Methods of treating brain disorders or identifying biomarkers related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019264583A Division AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Publications (1)

Publication Number Publication Date
AU2014361822A1 true AU2014361822A1 (en) 2016-07-28

Family

ID=53371976

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014361822A Abandoned AU2014361822A1 (en) 2013-12-13 2014-12-15 Treating brain disorders and biomarkers related thereto
AU2019264583A Abandoned AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019264583A Abandoned AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Country Status (9)

Country Link
US (1) US20160345855A1 (https=)
EP (2) EP3721799A1 (https=)
JP (2) JP2017500306A (https=)
CN (2) CN111920412A (https=)
AU (2) AU2014361822A1 (https=)
CA (1) CA2933372A1 (https=)
IL (2) IL246148A0 (https=)
MX (1) MX2016007716A (https=)
WO (1) WO2015089503A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
CN113557028A (zh) * 2019-01-11 2021-10-26 诺雷克斯股份有限公司 雷帕替奈的盐和晶型
CN110123342B (zh) * 2019-04-17 2021-06-08 西北大学 一种基于脑电波的网瘾检测方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
WO2007123799A2 (en) * 2006-04-03 2007-11-01 The Trustees Of The University Of Pennsylvania Assessing subject's reactivity to psychological stress using fmri
RU2496492C2 (ru) * 2006-06-15 2013-10-27 Марс, Инкорпорейтед Способы и композиции для улучшения когнитивной функции
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2834286A1 (en) * 2011-04-27 2012-11-01 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease

Also Published As

Publication number Publication date
EP3079579A4 (en) 2017-07-19
JP2017500306A (ja) 2017-01-05
IL276431A (en) 2020-09-30
WO2015089503A2 (en) 2015-06-18
EP3079579A2 (en) 2016-10-19
CN106102762A (zh) 2016-11-09
CN111920412A (zh) 2020-11-13
EP3721799A1 (en) 2020-10-14
CA2933372A1 (en) 2015-06-18
US20160345855A1 (en) 2016-12-01
IL246148A0 (en) 2016-07-31
AU2019264583A1 (en) 2019-12-05
MX2016007716A (es) 2017-03-31
WO2015089503A3 (en) 2015-10-01
JP2020007333A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
EP2813236A1 (en) GLYX for use in the treatment of depression or anxiety
CN101977606A (zh) 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法
AU2019264583A1 (en) Treating brain disorders and biomarkers related thereto
MX2012007778A (es) Diazoxido para su uso en el tratamiento o prevencion de una enfermedad desmielinizante autoinmunitaria del sistema nervioso central (snc).
AU2018286608A1 (en) A2a antagonists as cognition and motor function enhancers
JP2020128391A (ja) Ｎｍｄａ調節剤を使用するうつ病の治療方法
US20250179044A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
JP2017506233A (ja) クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ
JP2018065829A (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
US20120046302A1 (en) Methods of treating cns disorders
WO2020118282A1 (en) Methods, compositions and kits for treating multiple sclerosis and other disorders
WO2008137571A1 (en) Methods of treating neurodegenerative diseases
Rabins et al. Pathophysiology of involuntary emotional expression disorder
WO2010126527A1 (en) Methods of treating cns disorders
HK40040750A (en) Methods of treating brain disorders or identifying biomarkers related thereto
KR20230167032A (ko) 인지 장애의 치료를 위한 화합물
AU4301699A (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
US20190351006A1 (en) Methods of administration of nmda receptor agonists
CA2933730C (en) Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity
RU2450822C1 (ru) Применение гептапептида для лечения болезни паркинсона и способ лечения такой болезни
Toyohara et al. Roles of σ1 receptors in the mechanisms of action of CNS drugs
El Yacoubi et al. Theobromine and tryptophan alone or in association lack potential antidepressant-like effects whereas chronic paroxetine is effective in a genetic mouse model of depressive disorder
HK1237649A1 (zh) Nmdar调节化合物的组合

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted